Literature DB >> 25180631

ACR appropriateness Criteria® early-stage non-small-cell lung cancer.

Gregory M M Videtic1, Joe Yujiao Chang, Indrin J Chetty, Mark E Ginsburg, Larry L Kestin, Feng-Ming Spring Kong, Brian E Lally, Billy W Loo, Benjamin Movsas, Thomas E Stinchcombe, Henning Willers, Kenneth E Rosenzweig.   

Abstract

Early-stage non-small-cell lung cancer (NSCLC) is diagnosed in about 15% to 20% of lung cancer patients at presentation. In order to provide clinicians with guidance in decision making for early-stage NSCLC patients, the American College of Radiology Appropriateness Criteria Lung Cancer Panel was recently charged with a review of the current published literature to generate up-to-date management recommendations for this clinical scenario. For patients with localized, mediastinal lymph node-negative NSCLC, optimal management should be determined by an expert multidisciplinary team. For medically operable patients, surgical resection is the standard of care, with generally no role for adjuvant therapies thereafter. For patients with medical comorbidities making them at high risk for surgery, there is emerging evidence demonstrating the availability of low toxicity curative therapies, such as stereotactic body radiotherapy, for their care. As a general statement, the American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25180631     DOI: 10.1097/COC.0000000000000013

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs.

Authors:  Yusef A Syed; William Stokes; Manali Rupji; Yuan Liu; Onkar Khullar; Nikhil Sebastian; Kristin Higgins; Jeffrey D Bradley; Walter J Curran; Suresh Ramalingam; James Taylor; Manu Sancheti; Felix Fernandez; Drew Moghanaki
Journal:  Chest       Date:  2021-11-14       Impact factor: 9.410

2.  Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer.

Authors:  William A Stokes; Niya Xiong; Yuan Liu; Kristin A Higgins; Sibo Tian; Jeffrey D Bradley; Drew Moghanaki; Chad G Rusthoven
Journal:  Clin Lung Cancer       Date:  2022-01-10       Impact factor: 4.840

3.  [Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors 
(2017 Edition)].

Authors:  Xin Ye; Weijun Fan; Hui Wang; Junjie Wang; Shanzhi Gu; Weijian Feng; Yiping Zhuang; Baodong Liu; Xiaoguang Li; Yuliang Li; Po Yang; Xia Yang; Wuwei Yang; Junhui Chen; Rong Zhang; Zhengyu Lin; Zhiqiang Meng; Kaiwen Hu; Chen Liu; Zhongmin Peng; Yue Han; Yong Jin; Guangyan Lei; Bo Zhai; Guanghui Huang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-07-20

4.  Limits for the therapeutic application of the analytical anisotropic algorithm in the context of ablative lung radiotherapy near the minima of lung density and tumor size.

Authors:  Eric Lobb; Ahpa Plypoo
Journal:  J Appl Clin Med Phys       Date:  2022-05-09       Impact factor: 2.243

5.  Severe OSA associated with higher risk of mortality in stage III and IV lung cancer.

Authors:  Hung-Yu Huang; Shih-Wei Lin; Li-Pang Chuang; Chih-Liang Wang; Ming-Hui Sun; Hsueh-Yu Li; Chee-Jen Chang; Shu-Chen Chang; Cheng-Ta Yang; Ning-Hung Chen
Journal:  J Clin Sleep Med       Date:  2020-07-15       Impact factor: 4.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.